NUCANA PLC

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. NUCANA PLC 2017-08-29 → present
2. NUCANA LIMITED 2017-08-29 → 2017-08-29
3. NUCANA BIOMED LIMITED 2008-04-28 → 2017-08-29
4. BIOMED (UK) LIMITED 1997-01-28 → 2008-04-28

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Group's financial statements have been presented on the basis that it is a going concern. Based on the base case forecast, the Group believes that its cash and cash equivalents of £24.3 million at 31 December 2025 will be sufficient to fund the Group's anticipated operations for the entirety of the going concern assessment period. The directors do not consider that a situation where the Group would run out of cash over the going concern assessment period is plausible given the likelihood of such downside scenarios and the Group's ability to implement controllable mitigations.”

Group structure

1. NUCANA PLC · parent
   1. NuCana, Inc. 100% · U.S. · Development and administrative support
   2. NuCana BioMed Trustee Company Limited 100% · U.K. · Dormant
   3. NuCana BioMed Employee Benefit Trust 100% · U.K. · Employee benefit trust
   4. NuCana Limited 100% · Ireland · Development and administrative support

Significant events

• “In June 2025, we initiated an expansion of the Phase 2 part of the NuTide:701 study evaluating NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma and expect to report final data from this expansion study in 2026.”
• “In May 2025, we completed a registered direct offering, raising £9.6 million in gross proceeds, £5.2 million upfront and £4.4 million from the exercise of warrants.”
• “In June 2025, we entered into an "at-the-market" (ATM) sales agreement with A.G.P./Alliance Global Partners, or A.G.P., and Laidlaw & Company (UK) Ltd., or Laidlaw, pursuant to which we may periodically sell ADSs having an aggregate offering price of up to $100.0 million.”
• “During the year ended 31 December 2025 we sold and issued 394,303 ADSs, representing 9,857,575 ordinary shares, under the ATM program with Jefferies, raising gross proceeds of £0.5 million, and we sold and issued 450,758,552 ADSs, representing 11,268,963,800 ordinary shares, under the ATM program with A.G.P. and Laidlaw, raising gross proceeds of £19.0 million.”
• “On April 23, 2025, the Group subdivided and redesignated the issued share capital of 151,923,897 ordinary shares of £0.04 each into 151,923,897 ordinary shares and 15,040,465,803 deferred shares, in each case, of £0.0004 each.”
• “On 14 January 2026, the Group and the Company granted 3,851,136,696 share options to employees, consultants and directors pursuant to its existing share-based payment plans.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

20

last 12 months

Capital events

15

last 24 months

Officers appointed

0

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.